Wells Fargo’s Organogenesis Holdings ORGO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$58.8K Sell
24,797
-328,568
-93% -$1.14M ﹤0.01% 5392
2025
Q4
$1.83M Buy
353,365
+311,409
+742% +$1.51M ﹤0.01% 3518
2025
Q3
$177K Buy
41,956
+6,657
+19% +$30.9K ﹤0.01% 4999
2025
Q2
$129K Sell
35,299
-4,919
-12% -$18.3K ﹤0.01% 5042
2025
Q1
$174K Sell
40,218
-1,253
-3% -$5.06K ﹤0.01% 4802
2024
Q4
$133K Buy
41,471
+9,464
+30% +$31.8K ﹤0.01% 5040
2024
Q3
$91.5K Buy
32,007
+1,185
+4% +$3.32K ﹤0.01% 5071
2024
Q2
$86.3K Buy
30,822
+6,411
+26% +$17.2K ﹤0.01% 5013
2024
Q1
$69.3K Buy
24,411
+3,141
+15% +$10.7K ﹤0.01% 5104
2023
Q4
$87K Buy
21,270
+4,262
+25% +$11.9K ﹤0.01% 4992
2023
Q3
$54.1K Sell
17,008
-10,059
-37% -$32K ﹤0.01% 5136
2023
Q2
$89.9K Buy
27,067
+12,456
+85% +$36.8K ﹤0.01% 5114
2023
Q1
$31.1K Buy
14,611
+10,686
+272% +$26.4K ﹤0.01% 5429
2022
Q4
$10.6K Sell
3,925
-2,196
-36% -$6.41K ﹤0.01% 5531
2022
Q3
$20K Sell
6,121
-4,835
-44% -$21.8K ﹤0.01% 5401
2022
Q2
$54K Sell
10,956
-201,056
-95% -$1.24M ﹤0.01% 4986
2022
Q1
$1.61M Buy
212,012
+4,774
+2% +$37K ﹤0.01% 3493
2021
Q4
$1.92M Sell
207,238
-284,775
-58% -$3.02M ﹤0.01% 3547
2021
Q3
$7.01M Buy
492,013
+271,615
+123% +$4.22M ﹤0.01% 2531
2021
Q2
$3.66M Sell
220,398
-9,874
-4% -$184K ﹤0.01% 3149
2021
Q1
$4.2M Buy
230,272
+167,072
+264% +$2.26M ﹤0.01% 3008
2020
Q4
$476K Buy
63,200
+33,230
+111% +$158K ﹤0.01% 4557
2020
Q3
$115K Buy
29,970
+9,566
+47% +$37.8K ﹤0.01% 5202
2020
Q2
$78K Buy
20,404
+10,036
+97% +$36.2K ﹤0.01% 5340
2020
Q1
$33K Sell
10,368
-7,322
-41% -$31.3K ﹤0.01% 5476
2019
Q4
$85K Buy
17,690
+12,288
+227% +$77.9K ﹤0.01% 5358
2019
Q3
$36K Buy
5,402
+5,323
+6,738% +$29.6K ﹤0.01% 5654
2019
Q2
$1K Buy
+79
New +$581 ﹤0.01% 6268

Other funds holding ORGO

Wells Fargo's ORGO Position: Q1 2026 in Review

Wells Fargo reduced its Organogenesis Holdings (ORGO) stake by 93% in Q1 2026, selling an estimated $1.14M and leaving 24,797 shares worth $58.8K. The position accounts for ﹤0.01% of the portfolio, ranked #5392.

Wells Fargo first reported a position in ORGO in Q2 2019 and has held it in 28 quarters since. The position peaked at $7.01M in Q3 2021. 121 funds tracked by Wall St. Rank hold ORGO as of Q1 2026.

  • Wells Fargo held 24,797 shares of Organogenesis Holdings worth $58.8K as of Q1 2026.
  • Wells Fargo sold 328,568 Organogenesis Holdings shares in Q1 2026, an estimated $1.14M.
  • Organogenesis Holdings made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5392 holding.
  • Wells Fargo first reported a position in Organogenesis Holdings in Q2 2019 and has held it in 28 quarters since.
  • Wells Fargo's Organogenesis Holdings position peaked at $7.01M in Q3 2021.
  • 121 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.